ArticleJournal of diabetes and metabolic disorders2026
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with T2D. Tirzepatide has also been recently shown to be non-inferior to dulaglutide in cardiovascular risk reduction among patients with T2D. Whether tirzepatide is more or less effective than semaglutide for cardioprotection is underexplored. Methods: The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026. One-to-one propensity score matching was applied to control for possible confounding covariates. Results: two well-matched cohorts ( Conclusion: Tirzepatide was associated with lower risk of a composite of outcome of cardiovascular events as well as all-cause mortality compared to semaglutide in patients with T2D. Clinical trial registration: Clinical trial number: not applicable. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02087-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.